Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380

Through synthetic lethality screening of isogenic cell lines with and without the oncogenic KRAS gene and through lead compound optimization, we recently developed a novel anticancer agent designated NSC-743380 (oncrasin-72) that has promising in vitro and in vivo anticancer activity in a subset of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wu, Shuhong, Wang, Li, Huang, Xiao, Cao, Mengru, Hu, Jing, Li, Hongyu, Zhang, Hui, Sun, Xiaoping, Meng, Qing H., Hofstetter, Wayne L., Roth, Jack A., Swisher, Stephen G., Fang, Bingliang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4172508/
https://ncbi.nlm.nih.gov/pubmed/25182964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmc.2014.08.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak